|
1
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harris RC, Chung E and Coffey RJ: EGF
receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar
|
|
3
|
Arteaga CL and Baselga J: Tyrosine kinase
inhibitors: why does the current process of clinical development
not apply to them? Cancer Cell. 5:525–531. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galer CE, Corey CL, Wang Z, Younes MN,
Gomez-Rivera F, Jasser SA, Ludwig DL, El-Naggar AK, Weber RS and
Myers JN: Dual inhibition of epidermal growth factor receptor and
insulin-like growth factor receptor I: reduction of angiogenesis
and tumor growth in cutaneous squamous cell carcinoma. Head Neck.
33:189–198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C,
Johnson BE, Cantley LC and Jänne PA: MET amplification leads
to gefitinib resistance in lung cancer by activating ERBB3
signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar
|
|
6
|
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R,
Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor
receptor expression on survival and pattern of relapse in patients
with advanced head and neck carcinoma. Cancer Res. 62:7350–7356.
2002.PubMed/NCBI
|
|
7
|
Chung CH, Zhang Q, Hammond EM, Trotti AM
III, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH and
Ang KK: Integrating epidermal growth factor receptor assay with
clinical parameters improves risk classification for relapse and
survival in head-and-neck squamous cell carcinoma. Int J Radiat
Oncol Biol Phys. 81:331–338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galizia G, Lieto E, De Vita F, Orditura M,
Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab,
a chimeric human mouse anti-epidermal growth factor receptor
monoclonal antibody, in the treatment of human colorectal cancer.
Oncogene. 26:3654–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ,
Kussie P and Ferguson KM: Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
López-Albaitero A and Ferris RL: Immune
activation by epidermal growth factor receptor-specific monoclonal
antibody therapy for head and neck cancer. Arch Otolaryngol Head
Neck Surg. 133:1277–1281. 2007.PubMed/NCBI
|
|
11
|
Kurai J, Chikumi H, Hashimoto K, Yamaguchi
K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M,
Nakamoto M, Burioka N and Shimizu E: Antibody-dependent cellular
cytotoxicity mediated by cetuximab against lung cancer cell lines.
Clin Cancer Res. 13:1552–1561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung KY, Shia J, Kemeny NE, Shah M,
Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L,
Klimstra DS, Fridman D, Kelsen DP and Saltz LB: Cetuximab shows
activity in colorectal cancer patients with tumors that do not
express the epidermal growth factor receptor by
immunohistochemistry. J Clin Oncol. 23:1803–1810. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jonker DJ, O’Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ,
Tebbutt NC, van Hazel G, Wierzbicki R, Langer C and Moore MJ:
Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H,
Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA III:
EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, Loos AH, Zubel A and Koralewski P: Fluorouracil,
leucovorin and oxaliplatin with and without cetuximab in the
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D’Heans G, Pintér T, Lim R, Bodoky G,
Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M,
Nippgen J and Rougier P: Cetuximab and chemotherapy as initial
treatment for metastatic colorectal cancer. N Engl J Med.
360:1408–1417. 2009.PubMed/NCBI
|
|
17
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C,
Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus
cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies
MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herbst RS, Arquette M, Shin DM, Dicke K,
Vokes EE, Azarnia N, Hong WK and Kies MS: Phase II multicenter
study of the epidermal growth factor receptor antibody cetuximab
and cisplatin for recurrent and refractory squamous cell carcinoma
of the head and neck. J Clin Oncol. 23:5578–5587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baselga J, Trigo JM, Bourhis J, Tortochaux
J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A and
Eckardt A: Phase II multicenter study of the antiepidermal growth
factor receptor monoclonal antibody cetuximab in combination with
platinum-based chemotherapy in patients with platinum-refractory
metastatic and/or recurrent squamous cell carcinoma of the head and
neck. J Clin Oncol. 23:5568–5577. 2005.
|
|
21
|
Burtness B, Goldwasser MA, Flood W, Mattar
B and Forastiere AA; Eastern Cooperative Oncology Group. Phase III
randomized trial of cisplatin plus placebo compared with cisplatin
plus cetuximab in metastatic/recurrent head and neck cancer: an
Eastern Cooperative Oncology Group study. J Clin Oncol.
23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tejani MA, Cohen RB and Mehra T: The
contribution of cetuximab in the treatment of recurrent and/or
metastatic head and neck cancer. Biologics. 4:173–185.
2010.PubMed/NCBI
|
|
23
|
Sok JC, Coppelli FM, Thomas SM, Lange MN,
Xi S, Hunt JL, Freilino ML, Graner NW, Wikstrand CJ, Bigner DD,
Gooding WE, Furnari FB and Grandis JR: Mutant epidermal growth
factor receptor (EGFRvIII) contributes to head and neck cancer
growth and resistance to EGFR targeting. Clin Cancer Res.
12:5064–5073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen LF, Cohen EE and Grandis JR: New
strategies in head and neck cancer: understanding resistance to
epidermal growth factor receptor inhibitors. Clin Cancer Res.
16:2489–2495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim SM, Kim JS, Kim JH, Yun CO, Kim EM,
Kim HK, Solca F, Choi SY and Cho BC: Acquired resistance to
cetuximab is mediated by increased PTEN instability and leads
cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett.
296:150–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunn EF, Iida M, Myers RA, Campbell DA,
Hintz KA, Armstrong EA, Li C and Wheeler DL: Dasatinib sensitizes
KRAS mutant colorectal tumors to cetuximab. Oncogene. 30:561–574.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciardiello F, Bianco R, Caputo R, Caputo
R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco
AR and Tortora G: Antitumor activity of ZD6474, a vascular
endothelial growth factor receptor tyrosine kinase inhibitor, in
human cancer cells with acquired resistance to antiepidermal growth
factor receptor therapy. Clin Cancer Res. 10:784–793. 2004.
View Article : Google Scholar
|
|
28
|
Wheeler DL, Iida M, Kruser TJ, Nechrebecki
MM, Dunn EF, Armstrong EA, Huang S and Harari PM: Epidermal growth
factor receptor cooperates with Src family kinases in acquired
resistance to cetuximab. Cancer Biol Ther. 8:696–703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yonesaka K1, Zejnullahu K, Okamoto I,
Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M,
Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun
J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada
M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K,
Fukuoka M, Varella-Garcia M, Nakagawa K and Jänne PA: Activation of
ERBB2 signaling causes resistance to the EGFR-directed therapeutic
antibody cetuximab. Sci Transl Med. 3:99ra862011.PubMed/NCBI
|
|
31
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar
|
|
33
|
Todaro M, Alea MP, Di Stefano AB,
Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G,
Medema JP and Stassi G: Colon cancer stem cells dictate tumor
growth and resist cell death by production of interleukin-4. Cell
Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance
by preferential expression of the Akt/PKB survival pathway.
Oncogene. 27:1749–1758. 2008.
|
|
35
|
Salmaggi A, Boiardi Ak, Gelati M, Russo A,
Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La
Porta C, Alessandri G, Marras C, Croci D and De Rossi M:
Glioblastoma-derived tumorospheres identify a population of tumor
stem-like cells with angiogenic potential and enhanced multidrug
resistance phenotype. Glia. 54:850–860. 2006. View Article : Google Scholar
|
|
36
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thomas SM and Grandis JR: Pharmacokinetic
and pharmacodynamics properties of EGFR inhibitors under clinical
investigation. Cancer Treat Rev. 30:255–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, Shumacher KM, von Heydebreck A, Celik I and
O’Byrne KJ: EGFR expression as a predictor of survival for
first-line chemotherapy plus cetuximab in patients with advanced
non-small-cell lung cancer: analysis of data from the phase 3 FLEX
study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wheeler DL, Huang S, Kruser TJ,
Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and
Harari PM: Mechanisms of acquired resistance to cetuximab: role of
HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nevo J, Mattila E, Pellinen T, Yamamoto
DL, Sara H, Iljin K, Kallioniemi O, Bono P, Heikkilä P, Joensuu H,
Wärri A and Ivaska J: Mammary-derived growth inhibitor alters
traffic of EGFR and induces a novel form of cetuximab resistance.
Clin Cancer Res. 15:6570–6581. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hatakeyama H, Cheng H, Wirth P, Counsell
A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough
WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ and Chung CH:
Regulation of heparin-binding EGF-like growth factor by miR-212 and
acquired cetuximab-resistance in head and neck squamous cell
carcinoma. PLoS One. 5:e127022010. View Article : Google Scholar : PubMed/NCBI
|
